Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 13/20 | 0.55 |
| ▸ | ADRB1 | P08588 | 5/20 | 0.45 |
| ▸ | TLR4 | O00206 | 4/20 | 0.42 |
| ▸ | ADRB2 | P07550 | 5/20 | 0.40 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.38 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6075016 | 0.90 | ADRB3 (0.44) | ADRB3ADRB1TLR4ADRB2DNM1 | |
| SCHEMBL6074817 | 0.89 | ADRB3 (0.54) | ADRB3ADRB1TLR4ADRB2DNM1 | |
| SCHEMBL6986206 | 0.86 | ADRB3 (0.67) | ADRB3ADRB1TLR4ADRB2DNM1 | |
| SCHEMBL6074200 | 0.85 | ADRB3 (0.68) | ADRB3ADRB1TLR4ADRB2DNM1 | |
| SCHEMBL6074664 | 0.85 | AR (0.47) | ADRB3ADRB1ADRB2 | |
| SCHEMBL6074222 | 0.83 | ADRB3 (0.47) | ADRB3ADRB1TLR4ADRB2DNM1 | |
| SCHEMBL6075243 | 0.83 | ADRB3 (0.75) | ADRB3ADRB1TLR4ADRB2DNM1 | |
| SCHEMBL6074218 | 0.83 | ADRB3 (0.75) | ADRB3ADRB1TLR4ADRB2DNM1 | |
| SCHEMBL6985948 | 0.82 | ADRB3 (0.69) | ADRB3ADRB1TLR4ADRB2 | |
| SCHEMBL6074074 | 0.80 | ADRB3 (0.47) | ADRB3ADRB1TLR4ADRB2DNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7022716-B2 | Cyclic amine phenyl beta-3 adrenergic receptor agonists | WYETH (US) | 2006-04-04 | — | — | US | disclosed |
| US-20030144326-A1 | Cyclic amine phenyl beta-3 adrenergic receptor agonists | WYETH | 2003-07-31 | — | — | US | disclosed |
| US-6525202-B2 | E.g., substituted (4-amino-5-hydroxyphenyl)-oxy-)piperidinyl thiazolidin-2,4-dione; antidiabetic agents; atherosclerosis, gastrointestinal, metabolic disorders, glaucoma, neurogenetic inflammation, ocular hypertension and frequent urination | WYETH | 2003-02-25 | — | — | US | disclosed |
| US-20020028835-A1 | Cyclic amine phenyl beta-3 adrenergic receptor agonists | WYETH | 2002-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144326-A1 | Cyclic amine phenyl beta-3 adrenergic receptor agonists | ADRB1, ADRB3, ADRB2 | ADRB3 2/4885ADRB1 1/4885TLR4 630/4885 |
| US-20020028835-A1 | Cyclic amine phenyl beta-3 adrenergic receptor agonists | ADRB1, ADRB3, ADRB2 | ADRB3 2/4885ADRB1 1/4885TLR4 630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.